Advancing CGT Delivery, Regulatory Strategy with Axiom's Dr. Remo Moomiaie-Qajar

We love to hear from our listeners. Send us a message. In Episode 140 of Cell & Gene: The Podcast, Erin Harris speaks with Dr. Remo Moomiaie-Qajar of Axiom Biosciences about the company’s delivery-focused approach to developing regenerative and genetic medicines, including stem cell therapies, mRNA, and nanoparticles. Dr. Remo explains why drug delivery platforms can help shape therapeutic design and development strategy, and how evolving FDA guidance is creating opportunities to streamline preclinical requirements, leverage platform-based CMC data, and accelerate clinical development without compromising safety or quality. He also discusses the value of early regulatory engagement, clearer expectations, and stronger collaboration between developers and the FDA. Subscribe to the podcast! Apple  |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn